YOUR INVITATION TO ATTEND:

GeneSight® in Clinical Practice

A MYRIAD GENETICS SPEAKER PRESENTATION

A clinical and scientific discussion focusing on the basics of pharmacogenomics and review of the GeneSight® Psychotropic report and clinical data. Q&A to follow.

PRESENTER

Whitnee Brown, DNP, CRNP, FNP-C, PMHNP-BC

Dr. Whitnee Brown is a doctorally prepared, dually board-certified nurse practitioner in family practice and psychiatric mental health. Dr. Brown is a three-time graduate of Troy University where she earned a Bachelor of Science in Nursing (BSN), Masters of Science in Nursing (MSN) Family Nurse Practitioner Track, and Doctor of Nursing Practice (DNP). She earned her post-doctorate certification in Psychiatric Mental Health at The University of Alabama. She is the author of many peer-reviewed publications and the co-author of a Sigma Theta Tau International publication. Her research focuses on health promotion and wellness in underserved populations through technology.

DATE & TIME

Thursday, March 14, 2024
6:00pm

LOCATION

Mallard
3135 US-51
Summit, MS 39666

QUESTIONS

George Johnson
Sales Executive
george.johnson@myriad.com
(225) 936-5335

RSVP

Please RSVP by
March 12, 2024

TO REGISTER

Click Here to Register

This event is not open to the general public. If you were not the original recipient of this invitation, please contact a GeneSight representative with your request to attend.

The GeneSight® Psychotropic test is a genetics-based decision support tool that analyzes clinically important genetic variations that may affect your patient's outcomes with certain psychiatric medications. Use of the GeneSight Psychotropic test can help inform your medication selection. The results show which medications may require dose adjustments, may be less likely to work, or may have an increased risk of side effects based on your patient's genetic makeup. The clinical validity, clinical utility, and economic utility of the GeneSight Psychotropic test have been evaluated in seven published, peer-reviewed clinical trials. In the GUIDED study, patients in the GeneSight arm experienced an 11% relative improvement in symptoms, a 30% relative improvement in response rates, and a 50% relative improvement in remission rates compared to treatment as usual at week 8.

Myriad genetics

6960 Cintas Blvd
Mason, OH 45040
866.260.2394

genesight®
www.genesight.com

MNST.006.216